Radioactive tracers aim to spot Parkinson's in the brain

NCT ID NCT06949670

Recruiting now Diagnosis Sponsor: Tianjin Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing three new radioactive tracers that light up alpha-synuclein clumps in the brain during PET/CT scans. Researchers want to see if these scans can accurately diagnose Parkinson's disease and related disorders. 500 adults with suspected or confirmed Parkinson's will receive one injection and undergo imaging. The goal is to improve diagnosis, not to treat the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 (radioactive tracers for PET/CT imaging)
What this could lead to: If successful, this could lead to a more accurate way to diagnose Parkinson's disease and related conditions using brain imaging.
What could go wrong: This is an early diagnostic study, not a treatment. The tracers may not reliably detect alpha-synuclein in all patients, and results may not change clinical care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA SYNUCLEIN PATHOLOGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 Parkinson disease synucleinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPHA SYNUCLEIN PATHOLOGY ALPHA-SYNUCLEIN PARKINSON DISEASE

Contacts and locations

Locations

The First Affiliated Hospital of University of Science and Technology of China
RECRUITING

Hefei, Anhui, 350005, China
Tianjin Medical University General Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.